News & Updates

Certain individuals initially testing negative for tuberculosis (TB) by interferon-gamma release assay (IGRA) may later contract the infection and therefore require extended follow-up due to increased risk, as reported in a study from Singapore.

A recent study has found no evidence supporting the association of intraocular pressure (IOP) fluctuation, as measured in clinical practice, with visual field (VF) progression in patients with glaucoma.

A treat-and-extend personalized treatment with faricimab based on disease activity results in sustained gains in vision or anatomic outcomes through 2 years in patients with neovascular age-related macular degeneration (nAMD), reports a study. Moreover, nearly four in five (80 percent) patients have achieved extended dosing intervals of 12 weeks or more.

Individuals with obesity who underwent a short-term, low-calorie diet demonstrate a multifaceted body response, including an increased brain connectivity in the limbic‒temporal network (emotion and memory) as well as hormone and eating behaviour changes that seem relevant for recovering the weight lost, a recent study has shown.

The addition of dostarlimab to a carboplatin-paclitaxel (CP) chemotherapy regimen confers an overall survival (OS) benefit in women with primary advanced or recurrent endometrial cancer (EC), according to the second interim analysis of the ENGOT-EN6/GOG-3031/RUBY trial part 1.

Prothrombin complex concentrate (PCC) treatment does not improve functional outcomes or reduce haematoma expansion or mortality in Chinese atrial fibrillation (AF) patients with direct-acting oral anticoagulant (DOAC)–associated intracerebral haemorrhage (ICH), researchers from the Chinese University of Hong Kong (CUHK) have reported.

A novel, stimuli-responsive hydrogel implant for reversible occlusion of the fallopian tubes holds promise for preventing pregnancy and endometriosis or halting the latter’s spread, as reported in a study.

A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.